NCT03602079

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

CompletedPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2018-07-16Est. Completion: 2022-01-12

Enrollment target: 49 participants

Locations

Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
Beth Israel Deaconess Medical Center Cancer Center, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Clinical Research Alliance, Inc., Lake Success, New York, United States
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Providence Cancer Institute, Portland, Oregon, United States
Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas, United States
Virginia Cancer Specialist, Fairfax, Virginia, United States

Other microbiome trials you might be interested in

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid TumorsPhase 1Recruiting

Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Non-small Cell Lung Cancer (NSCLC)HR+/HER2- Ductal Breast Cancer (BC)HR+/HER2- Lobular Breast Cancer (BC)Triple Negative Breast Cancer (TNBC)Colorectal Cancer (CRC)Soft Tissue Sarcoma (STS)

The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokine…

Chuo Ku, JapanEst. completion Jan 16, 2028

View Trial →

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)Phase 1Recruiting

HER2 Expressing Solid Tumors

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.